Real world multiple myeloma registry from jordan, a developing country.

Conclusion: MM in a developing country presents a challenging disease compared with that in industrial countries in both the epidemiology and management. An improved road map in the care of MM in these countries is needed. The use of three or four drug combination upfront is warranted. However, this is limited because of the high cost of these drugs. We expect the following decade to show better survival and quality of life for MM patients once these drugs are widely used.KEYWORDS: MYELOMA, DEVELOPING COUNTRIES, JORDAN, NEW THERAPIES, THERAPY COST.

Source: Mediterranean Journal of Hematology and Infectious Diseases - April 28, 2022 Category: Hematology Authors: Abdalla Awidi, Farah Qasem, A ' sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa ”neh, Feras Al-fararjeh Source Type: research